Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Kühnl

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Journal of Hematology|July 14, 2012
Molecular markers in acute myeloid leukaemiaAndrea Kühnl, David Grimwade
Cancer Treatment Reviews|August 20, 2017
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphomaAndrea Kühnl, David Cunningham, Ian Chau
Expert Review of Hematology|November 20, 2015
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomasBenjamin Kasenda, Andrea Kühnl, Ian Chau
European Journal of Pharmacology|July 1, 2008
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancerHongyu Liu, Chuanbing Zang, Anna Emde, et al.
Leukemia Research|June 24, 2010
The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemiaEbru Coskun, Eva Kristin von der Heide, Cornelia Schlee, et al.
Blood|January 13, 2010
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemiaAndrea Kühnl, Nicola Gökbuget, Andrea Stroux, et al.
BMC Hematology|August 22, 2018
Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patientsAndrea Kühnl, David Cunningham, Margaret Hutka, et al.
Blood|October 20, 2011
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemiaAndrea Kühnl, Nicola Gökbuget, Martin Kaiser, et al.
Leukemia Research|September 9, 2011
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaAndrea Kühnl, Martin Kaiser, Martin Neumann, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Hematology|July 14, 2012
Molecular markers in acute myeloid leukaemiaAndrea Kühnl, David Grimwade
Cancer Treatment Reviews|August 20, 2017
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphomaAndrea Kühnl, David Cunningham, Ian Chau
Expert Review of Hematology|November 20, 2015
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomasBenjamin Kasenda, Andrea Kühnl, Ian Chau
European Journal of Pharmacology|July 1, 2008
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancerHongyu Liu, Chuanbing Zang, Anna Emde, et al.
Leukemia Research|June 24, 2010
The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemiaEbru Coskun, Eva Kristin von der Heide, Cornelia Schlee, et al.
Blood|January 13, 2010
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemiaAndrea Kühnl, Nicola Gökbuget, Andrea Stroux, et al.
BMC Hematology|August 22, 2018
Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patientsAndrea Kühnl, David Cunningham, Margaret Hutka, et al.
Blood|October 20, 2011
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemiaAndrea Kühnl, Nicola Gökbuget, Martin Kaiser, et al.
Leukemia Research|September 9, 2011
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaAndrea Kühnl, Martin Kaiser, Martin Neumann, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Pageof 2